
GRI Bio, Inc. (NASDAQ:GRI – Free Report) – Analysts at HC Wainwright decreased their FY2026 earnings per share (EPS) estimates for shares of GRI Bio in a research report issued on Monday, November 16th. HC Wainwright analyst M. Keller now forecasts that the company will earn ($3.63) per share for the year, down from their prior estimate of ($3.36). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for GRI Bio’s current full-year earnings is ($3.88) per share. HC Wainwright also issued estimates for GRI Bio’s Q4 2026 earnings at ($0.73) EPS, FY2027 earnings at ($0.20) EPS and FY2028 earnings at ($0.16) EPS.
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of GRI Bio in a research note on Thursday, October 15th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, GRI Bio has an average rating of “Hold” and an average target price of $21.00.
GRI Bio Stock Down 11.8%
GRI Bio stock opened at $1.12 on Wednesday. GRI Bio has a 12-month low of $1.09 and a 12-month high of $64.12. The firm’s 50-day moving average is $1.70 and its two-hundred day moving average is $2.02.
GRI Bio (NASDAQ:GRI – Get Free Report) last released its quarterly earnings results on Friday, November 13th. The company reported ($0.69) earnings per share for the quarter, topping the consensus estimate of ($0.84) by $0.15.
About GRI Bio
GRI Bio is a clinical-stage biotechnology company developing therapies for inflammatory, fibrotic and autoimmune diseases. Its research focuses on invariant natural killer T (iNKT) cells, a type of immune cell involved in regulating inflammation and immune responses. The company’s lead candidate, GRI-0621, is an oral investigational therapy being developed for idiopathic pulmonary fibrosis, a progressive lung disease. GRI Bio is also advancing other drug candidates that target iNKT-cell biology for potential use in immune-mediated conditions.
Featured Articles
- Five stocks we like better than GRI Bio
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for GRI Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRI Bio and related companies with MarketBeat.com's FREE daily email newsletter.
